Healthcare
Lonza Group AG(LZAGY)
Live Price
Offline$61.20
-0.03% today
1Y Change
-12.68%
Window
Jun 25, 2025 โ Jun 18, 2026
- Market Cap
- $33.47B
- Revenue Growth
- -0.7%
- EPS Growth
- +52.8%
- Dividend Yield
- 0.8%
Coverage: 247 bars ยท Jun 25, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Lonza Group AG (LZAGY) is a Healthcare stock with a market cap of $33.47B and listed on OTC. The stock last traded around $61.20 and down 12.7% across the available one-year price window (Jun 25, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of -0.7%, EPS growth of +52.8%, a dividend yield of 0.8%. What stands out right now is revenue -0.7%, EPS +52.8%, free cash flow -36.2% with operating margin 21.0% and ROIC 7.2%. The dividend is present but secondary, with a yield around 0.8%. Valuation already assumes a fairly strong business story at P/E 37.0 and price/sales 5.1. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines LZAGY price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-0.7% vs +7.6% peer median
Operating Margin
Near sector median
+21.0% vs +19.4% peer median
P/E
Near sector median
37.0 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report came in below the EPS bar
2026 was reported on Jan 28, 2026 with an EPS surprise of -5.9% and a revenue surprise of -9.3%.
The operating picture looks softer than before
Revenue is at -0.7% and EPS is at +52.8%, with operating margin around 21.0%.
The next real check-in already has a date
The next earnings event is scheduled for Jul 22, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -2.3% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Jan 28, 2026 | -5.9% | -0.8% | -4.3% | -2.4% |
2025 Jul 23, 2025 | -12.1% | -1.8% | -2.8% | -1.7% |
2025 May 14, 2025 | -46.2% | +0.6% | +0.2% | +1.5% |
Benchmark Edge
LZAGY vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
LZAGY
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
LZAGY Max Drawdown
-20.23%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for LZAGY and SPY.
Company Overview
Lonza Group AG
Other OTC
Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia and New Zealand, and internationally. It operates through Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients segments. The Biologics segment engages in the contract development and manufacturing of biopharmaceuticals for clinical and commercial manufacturing needs throughout the product lifecycle, including drug substance and drug product manufacturing. The Small Molecules segment operates as an integrated development and manufacturing service provider for small molecule drug substances and their intermediates. It supports customers across various aspects of design, development, and manufacturing. The Cell & Gene segment develops technologies and platforms that industrialize the manufacturing processes and production of cell and gene therapies. It also offers contract development and manufacturing services, and regulatory support for a range of allogeneic and autologous cell therapies, and exosome-based therapies, as well as viral vector gene therapies. In addition, this segment provides specialty raw materials and enabling technology solutions in cell and gene therapy, injectable drugs, vaccines, and bio-manufacturing markets. The Capsules & Health Ingredients segment offers capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical customers. The company was founded in 1897 and is headquartered in Basel, Switzerland.
- Leadership
- Wolfgang Wienand
- IPO Date
- Jan 20, 2010
- Employees
- 18.0k
- Street Address
- Muenchensteinerstrasse 38
- Mailing
- Basel, 4002
- Region
- Basel, CH
- Reporting Currency
- USD
- Investor Line
- 41 61 316 81 11
- Last Updated
- May 2, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 37.0
- EV/EBITDA
- 20.4
- Price/Sales
- 5.1
- Price/Book
- 3.7
Growth
- Revenue
- -0.7%
- EPS
- +52.8%
- Free Cash Flow
- -36.2%
Profitability
- Gross Margin
- 34.6%
- Operating Margin
- 21.0%
- Net Margin
- 13.9%
- ROE
- 10.2%
- ROIC
- 7.2%
Balance Sheet
- Debt/Equity
- 0.46
- Current Ratio
- 2.24
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.